Note: Descriptions are shown in the official language in which they were submitted.
CA 02436260 2003-07-22
1
Compositions containing a ruthenium(lll) complex and a heterocycle
This invention relates to compositions which include a ruthenium(I11) complex
and a
heterocycle and also to their application as medicaments for the treatment of
cancer
illnesses.
The possible applicability of ruthenium complexes in the treatment of cancer
illnesses
has been discussed by M.J. Clarke, ACS Symp. Ser. 140 (1980) 157 - 180.
Complex compounds of trivalent ruthenium with pyrazole and imidazole have been
described by F. Kralik et al., Collection Czechoslov. Chem. Commun. 26 (1961)
1298
and by B.K. Keppler et al., lnorg. Chem., 26 (1987) 4366 - 4370.
Furthermore, ruthenium(III) complexes with indazole and dimethyl sulfoxide
have been
investigated by B.K. Keppler et al., Anticancer Res., 9 (1989) 761 - 766, G.
Mestroni et
al., J. Am. Chem. Soc. 111 (1989) 7068 - 7071 and G. Mestroni et al., Inorg.
Chem., 34
(1995) 4722 - 4734.
The tumour-inhibiting properties of ruthenium(III) complexes with a basic
heterocycle,
such as indazole, are also described in Eur. J. Inorg. Chem. 1999, 9, pp. 1551
- 1555,
Met.-Based Drugs 1994, 1 (2-3), pp. 145 - 150 and J. Cancer Res. Clin. Oncol.
1992,
118(3), pp. 195 - 2000.
In the US PS 4,843,069 medicaments are described which contain ruthenium(Ill)
complexes with a monocyclic or multi-cyclic basic heterocycle. The complexes
are
suitable for cancer therapy, but are difficult to dissolve in water and are
therefore not
lyophilisable.
To avoid this disadvantage, W097/36595 discloses ruthenium(III) complexes with
an
alkali metal cation or with ammonia which are easily soluble in water and
which are also
effective in the treatment of cancer illnesses. However, these compounds have
the
CA 02436260 2007-08-10
2
disadvantage that they exhibit a lower effectiveness than ruthenium complexes
according to US PS 4,843,069.
Therefore, the object of the invention is to avoid the disadvantages mentioned
above and to provide a composition which is easily water-soluble and which
exhibits a high effectiveness in the treatment of cancer illnesses.
This object is solved by a composition (A) obtained by reacting a compound of
the general formula (I)
M3-n-p-2pr[RUX6-n-p-Q-2rBn(H20)p(OH)Q(O)r]2r+1 (I)
where
M is an alkali metal cation or ammonia,
B is a monocyclic or multi-cyclic basic heterocycle with one or more nitrogen
atoms,
X is a halide, pseudo-halide, HC03 , or RCOO-, in which R is a substituted or
unsubstituted C,-Cs-alkyl or C2-C6-alkenyl or a substituted or unsubstituted
aryl,
n = 1 or 2,
p, q=0or1 or(ifr=0.5)0or0.5, and
r = 0 or 0.5,
with a compound of the formula (II)
B'(HX')s (II)
where
B' is a monocyclic or multi-cyclic basic heterocycle with one or more nitrogen
atoms,
X' is a halide, pseudo-halide, HC03 , or RCOO-, in which R is hydrogen or a
substituted or unsubstituted C,-C6-alkyl or C2-C6-alkenyl or a substituted or
unsubstituted aryl, phosphate, sulphate and/or acetate, and
CA 02436260 2007-08-10
3
s in an integer of 1 or more.
The obtained composition actually comprises a mixture of:
(i)a compound of the general formula (III)
(B'H)3-n-p-2pr[RuXs-n-p-4-2rBn(H20)p(OH)q(O)rI 2r,1 (III)
where
B, B' is a monocyclic or multi-cyclic basic heterocycle with one or more
nitrogen
atoms,
X is a halide, pseudo-halide, HCO3 , or RCOO-, in which R is a substituted or
unsubstituted C,-C6-alkyl or C2-Cs-alkenyl or a substituted or unsubstituted
aryl,
n = 1 or 2,
p,q=0or1 or(ifr=0.5)0or0.5,and
r= 0 or 0.5,= and
(ii )a compound of the formula (IV)
MX' (IV)
where
M is an alkali metal cation or ammonia and
X' is a halide, pseudo-halitle, HC03 , or RCOO-, in which R is hydrogen or a
substituted or unsubstituted C,-C6-alkyl or C2-C6-alkenyl or a substituted or
unsubstituted aryl, phosphate, sulphate or acetate.
The obtained composition may also comprise a compound of the formula (II) as
mentioned hereinabove.
B and/or B' in the formulae (I), (II) or (III) can be purine, adenine,
guanine,
cytosine, indazole, imidazole, pyrazole, pyridine, pyrimidine, pyridazine,
pyrrole,
tetrazole and/or triazine which can be substituted by one or more
substituents,
selected from the group consisting of:
CA 02436260 2003-07-22
4
hydroxyl, amino, halogen, C,-C4-alkyl, C2-C4-alkenyl, Cl-C4-alkyl mercapto,
formyl-, Cl-
C4-alkoxy carbonyl, Cl-C4-alkoxy carbonyl-Cl-C4-alkylen, di-Cl-C4-alkyl-amino,
di-Cl-
C4-alkyl-amino-C,-C4-alkylen, di-Cl-C4-alkyl-amino-carbonyl, di-Cl-C4-alkyl-
amino-
carbonyl-Cl-C4-alkylen, hydroxy imino methine, phenyl, benzyl, benzoyl,
pyrrolidino,
piperidino, pyrrol-1-yi and pyrrol-1-yl-Cl-C4-alkylen
or a ring
W Y
I ~I
RZ N
Rl'
where
- R1' is hydrogen, sodium, Cl-C4-alkyl or phenyl and
- R2' is hydrogen, Cl-C4-alkyl, amino or phenyl, or R1' and R2' together
represent
a group -(CH2)s- where s is an integer from 4 to 8,
- W is nitrogen or CR3', where R3' is a hydrogen, Cl-C4-alkyl, amino or
phenyl,
preferably hydrogen or methyl,
- Y is nitrogen or CR4' where R4' is a hydrogen, C1-C4-alkyl, amino or phenyl,
preferably hydrogen or methyl, and
- Z is nitrogen or CR5' where R5' is a hydrogen, Cl-C4-alkyl, amino or phenyl,
preferably hydrogen or methyl, whereby the ring is bonded to the basic
heterocycle B or B' by at least one of the substituents R1' and R2'.
Preferably at least one of the groups R3', R4' or R5' is a hydrogen.
Preferably the at least one substituent is selected from the group consisting
of chlorine,
diethylamino, dimethylamino and pyrrol-1-yl-methyl.
CA 02436260 2007-08-10
In a preferred embodiment B and/or B' in the formulae (I), (II) or (III) can
be 1-
methylimidazole, 4-methylimidazole, 4-methylpyrazole, 1-sodium pyrazole, 1-
phenyltetrazole or 5-phenyltetrazole which can be substituted, preferably in
position 4
by one or more substituents, as defined above.
In a further preferred embodiment B and/or B' in the formulae (I), (II) or
(III) are
imidazole, pyrazole, triazole or indazole, with imidazole, triazole or
indazole being
particularly preferred, but more preferably triazole or indazole, especially
indazole.
B' and B can be the same, i.e. they can represent the same heterocycle.
Furthermore, M in the formulae (I) and (IV) is preferably lithium, sodium or
potassium,
especially sodium.
In the preferred embodiments X and/or X' in the formulae (1), (II), (111) or
(IV) are chlorine
or bromine, especially chlorine. In another preferred embodiment X' in the
composition
(A) or (B) corresponds to X.
The molar ratio of the compound of formula (I) to the compound of formula (II)
used to prepare the composition according to the invention is preferably <1, a
ratio between 1:1.1 and 1:10 is particularly preferred, and especially 1:2 and
1:5.
The molar ratio of the compound of formula (III) to the compound of formula
(IV) in the
composition according to the invention is preferably a ratio between 1:2 and
1:30,
with 1:5 and 1:15 being particularly preferred, with 1:10 being especially
preferred.
In a preferred embodiment the compound of formula (I) is sodium trans-
tetrachlorobis(1 H-indazole)-ruthenate(I I I).
The compound of formula (II) is preferably indazolium hydrochloride.
CA 02436260 2003-07-22
6
The compound of formula (III) is preferably indazolium trans-[tetrachlorobis-
(indazole)ruthenate(I I I)].
The compound of formula (IV) is preferably sodium chloride.
The composition (A) or (B) according to the invention can be present in the
form of an
aqueous solution.
The composition (B) can be obtained by attrition of a compound of the formula
(III) with
a compound of formula (IV) in mortars or mills, such as air stream or ball
mills.
It was surprisingly found that the availablility of a compound of the general
formula (III)
in aqueous solution can be improved by mixing with a compound of the general
formula
(IV) while obtaining the composition (B).
It was also surprisingly found that a compound of the general formula (I),
which is
slightly soluble in water and lyophilisable, offers suitable formulation
methods by
reaction with a compound of the general formula (II) to form a composition (A)
according
to the invention suitable for the treatment of cancer illnesses (see Examples
1-3 and
Figures 1-4).
Furthermore, the object of the invention is solved by a medicament which
contains the
compositions (A) and/or (B) according to the invention.
The compositions (A) and/or (B) can furthermore be employed in the manufacture
of a
medicament for the prophylaxis and/or treatment of cancer illnesses.
The medicament according to the invention is described in more detail in the
following.
The medicaments according to the invention are primarily administered
intravenously,
but also intramuscularly, intraperitoneally, subcutaneously or perorally.
External
CA 02436260 2003-07-22
7
application is also possible. Administration through intravenous injection or
infusion is
preferred.
The pharmaceutical preparations are produced by known methods whereby the
composition according to the invention is used on its own or, where necessary
in
combination with suitable pharmaceutical carrier substances. If the
pharmaceutical
preparations contain pharmaceutical carrier substances as well as the active
substance,
the content of active substance in these mixtures is 0.1 to 99.5%, preferably
0.5 to 95%
by weight of the total mixture.
The active substance can be applied in any suitable formulation with the
requirement
that the formation or maintenance of a sufficient level of active substance is
ensured.
This can, for example, be achieved through oral or parenteral administration
in suitable
doses. Advantageously, there is the pharmaceutical preparation of the active
substance
in the form of standard doses, which are adapted to the desired
administration. A
standard dose may be, for example, a tablet, dragee, capsule, suppository or a
measured volume of a powder, a granulate, solution, emulsion or suspension.
A "standard dose" in the sense of this invention is taken to mean a physically
determined unit which contains an individual quantity of the active
constituent in
combination with a pharmaceutical carrier substance and its content of active
substance
corresponds to a fraction or multiple of a therapeutic single dose. A single
dose
preferably contains the quantity of active substance which is administered
during an
application and which normally corresponds to a whole, half, third or quarter
of the daily
dose. If only a fraction, such as half or quarter of the standard dose is
needed for a
single therapeutically administered dose, then the standard dose is
advantageously
divisible, e.g. in the form of a tablet with a dividing groove.
The medicaments according to the invention can, if they are available in
standard doses
and intended for application, e.g. on persons, contain about 0.1 to 500 mg,
preferably
to 200 mg and particularly 50 to 150 mg of active substance.
CA 02436260 2003-07-22
8
Generally in human medicine, the active substance(s) are administered in a
daily dose
of 0.1 to 5, preferably 1 to 3 mg/kg of body weight, where necessary in the
form of a
number, preferably 1 to 3, of single intakes for achieving the desired
results. A single
intake contains the active substance(s) in quantities of 0.1 to 5, preferably
1 to 3 mg/kg
of body weight. With oral treatment similar dosages can be applied.
The therapeutic administration of pharmaceutical preparations can occur 1 to 4
times
daily at specified or varying time points, e.g. in each case before meals
and/or in the
evening. However, it may be necessary to deviate from the quoted dosages
depending
on the type, body weight and age of the individual to be treated, the type and
severity of
the illness, the type of preparation and the application of the pharmaceutical
preparations as well as the time period or interval within which the
administration
occurs. Consequently, in some cases it may be sufficient to use less than the
amount of
active substance mentioned above, whereas in other cases the above listed
quantities
of active substance must be exceeded. It may also be practicable to administer
the
pharmaceutical preparations only once or at intervals of several days.
The specification of the necessary optimum dosage and type of application of
the active
substance can be made by any specialist based on his specialist knowledge.
The pharmaceutical preparations normally comprise the composition according to
the
invention and non-toxic, pharmaceutically compatible medication carriers which
are
employed as admixtures or diluting agents for example in solid, semi-solid or
liquid form
or as a means of enclosure, for example in the form of a capsule, a tablet
coating, a bag
or another container for the therapeutically active constituent. A carrier
material may, for
example, act as an agent for the ingestion of the medicament by the body, as a
formulation agent, sweetener, taste modifier, colorant or as preservative.
For oral application, for example, tablets, dragees, hard and soft capsules,
for example
of gelatine, dispersible powder, granulate, aqueous and oily suspensions,
emulsions,
solutions and syrups can be employed.
CA 02436260 2003-07-22
9
Tablets can contain inert binding agents, e.g. calcium carbonate, calcium
phosphate,
sodium phosphate or lactose; granulation and distributing agents, e.g. maize
starch or
alginates; binding agents, e.g. starch, gelatine or arabine; and lubricating
agents, e.g.
aluminium or magnesium stearate, talcum or silicone oil. They can also be
provided with
a coating which is produced such that it causes delayed release and resorption
of the
pharmaceutical preparation in the gastro-intestinal tract, so that, for
example, improved
compatibility, assimilation or retardation is achieved. Gelatine capsules may
contain the
pharmaceutical substance with a solid, e.g. calcium carbonate or kaolin or an
oily, e.g.
olive, peanut or paraffin oil dilution agent.
Aqueous suspensions can contain suspension agents, e.g. sodium carboxymethyl
cellulose, methyl cellulose, hydroxypropyl cellulose, sodium alginate,
polyvinyl
pyrrolidon, traganth rubber or arabine; dispersant or wetting agents,. e.g.
polyoxyethylene stearate, heptadeca-ethylene-oxycatanol, polyoxyethylene
sorbitol-
monooleate, or lecithin; preservatives, e.g. methyl- or propylhydroxy-
benzoate; taste
modifiers; sweeteners, e.g. saccharose, lactose, sodium cyclamate, dextrose,
invert
sugar syrup.
Oily suspensions may be, for example, peanut, olive, sesame, coconut or
paraffin oil
and thickening agents, such as bees wax, high melting point wax or cetyl
alcohol; also
sweeteners, taste modifiers and antioxidants.
Powder and granulates dispersible in water may contain the composition
according to
the invention in a mixture with dispersing, wetting and suspension agents,
e.g. those
mentioned above as well as with sweeteners, taste modifiers and colorants.
Emulsions can, for example, contain olive, peanut or paraffin oil as well as
emulsifying
agents such as arabine, traganth rubber, phosphatides, sorbitan monooleate,
polyoxyethylene sorbitan monooleate and sweeteners and taste modifiers.
CA 02436260 2003-07-22
Aqueous solutions can contain preservatives, e.g. methyl- or
propylhydroxybenzoates;
thickening agents; taste modifiers; sweeteners, e.g. saccharose, lactose,
sodium
cyclamate, dextrose, invert sugar syrup as well as taste modifiers and
colorants.
For the parenteral application of pharmaceutical substances sterile injectable
aqueous
solutions, isotonic salt solutions or other solutions can be used.
As a menstruum for infusion any suitable solution can be used. Water and
Haemaccel
are preferred.
The method according to the invention for the production of the composition
(A)
includes the reaction of a complex compound of the formula (I) with a compound
of the
formula (II). The reaction preferably takes place in an aqueous solution.
The method according to the invention for the production of the composition
(B)
includes mixing a complex compound of the formula (III) with a compound of the
formula (IV). Here, a compound of the formula (III) is put through attrition
with a
compound of the formula (IV), e.g. in the mortar or in ball mills.
Furthermore, a kit (A) is made available which comprises a receptacle with a
compound
of the formula (I)
M3-n-p-2pr[RuX6-n-p-Q-2rBn(H20)p(OH)a(O)r]2r+1 (I)
where
M is an alkali metal cation or ammonia,
B is a monocyclic or multi-cyclic basic heterocycle with one or more nitrogen
atoms,
X is a halide, pseudo-halide, HC03 , or RCOO-, in which R is a substituted or
unsubstituted C1-C6-alkyl or C2-C6-alkenyl or a substituted or unsubstituted
aryl,
n = 1 or2,
p,q=0or1 or(ifr=0.5)0or0.5,and
CA 02436260 2003-07-22
11
r = 0 or 0.5,
as well as a receptacle with a compound of the formula (II)
B'(HX')s (II)
where
B' is a monocyclic or multi-cyclic basic heterocycle with one or more nitrogen
atoms,
X' is a halide, pseudo-halide, HC03 , or RCOO-, in which R is hydrogen or a
substituted or unsubstituted Cl-C6-alkyl or C2-C6-alkenyl or a substituted or
unsubstituted aryl, phosphate, sulphate, acetate, and
s is an integer of 1 or more.
In a preferred embodiment X' in kit (A) is the same radical as X and B the
same radical
as B'.
Also, a kit (B) is made available which comprises a receptacle with a compound
of the
formula (III)
(B'H)3-n-p-2prLRUXg-n-p-9-2rBn(H20)p(OH)4(O)rJ2r+i (III)
where
B, B' is a monocyclic or multi-cyclic basic heterocycle with one or more
nitrogen
atoms,
X is a halide, pseudo-halide, HC03 , or RCOO-, in which R is a substituted or
unsubstituted C,-C6-alkyl or C2-C6-alkenyl or a substituted or unsubstituted
aryl,
n = 1 or2,
p,q=0or1 or(ifr=0.5)0or0.5,and
r = 0 or 0.5,
as well as a receptacle with a compound of the formula (IV)
CA 02436260 2003-07-22
12
MX' (IV)
where
M is an alkali metal cation or ammonia,
X' is a halide, pseudo-halide, HC03 , or RCOO-, in which R is hydrogen or a
substituted or unsubstituted Cl-C6-alkyl or C2-C6-alkenyl or a substituted or
unsubstituted aryl, phosphate, sulphate or acetate.
To the radicals X, X', B and B' the same applies as for the above kit (A).
In the following the kit (A) according to the invention is explained in more
detail.
In the clinic the application of the composition (A) according to the
invention on the
patient can take place through the provision of a kit which contains an
ampoule with a
compound of the formula (I), preferably as sodium salt, as well as separately
an infusion
solution which contains an equimolar or also a higher concentration of a
compound of
the formula (II), preferably as hydrochloride. Before the application on the
patient, the
content of the ampoule dissolved in water can be injected into the infusion
bottle. In this
way the composition (A) according to the invention is formed which can then be
immediately used on the patient.
In the following the kit (B) according to the invention is explained in more
detail.
In the clinic the application of the composition (B) according to the
invention on the
patient can take place through the provision of a kit which contains an
ampoule (1) with
a compound of the formula (III), preferably as indazolium salt, as well as
separately an
ampoule (2) with a compound of the formula (IV), e.g. sodium chloride, as well
as a
menstruum for the infusion. Before the application on a patient the content of
the
ampoule (1) is put through attrition, e.g. in a mortar with the content of
ampoule (2)
under retention of the composition (B) according to the invention. Then the
compound
CA 02436260 2003-07-22
13
(B), dissolved in the menstruum for infusion, can be injected into the
infusion bottle and
immediately used on the patient.
Fig. 1 shows a comparison of the cytotoxic effects of KP 1019, of the
corresponding
sodium salt KP 1339, indazole as well as the equimolar mixture of KP 1339 and
indazole (administered as a solution in a conventional cell culture medium
MEM,
supplemented with 10% of foetal bovine serum, without the addition of organic
solvents
or dissolving agents) on the human line of tumour cells SW480 (colon
carcinoma) in the
MTT assay with continuous 96 hour exposure to the active substance.
Fig. 2 shows a comparison of the cytotoxic effects of KP 1019, of the
corresponding
sodium salt KP 1339, indazole as well as the equimolar mixture of KP 1339 and
indazole (administered as a solution in a conventional cell culture medium
MEM,
supplemented with 10% of foetal bovine serum, without the addition of organic
solvents
or dissolving agents) on the human line of tumour cells CH1 (ovarian
carcinoma) in the
MTT assay with continuous 96 hour exposure to the active substance.
Fig. 3 shows a comparison of the cytotoxic effects of KP 1019, indazole and of
mixtures
of KP 1339 and indazole in the molar ratios 1:1 respectively 1:5 (administered
as a
solution in a conventional cell culture medium MEM, supplemented with 10% of
foetal
bovine serum, without the addition of organic solvents or dissolving agents)
on the
human line of tumour cells SW480 (colon carcinoma) in the MTT assay with
continuous
96 hour exposure to the active substance.
Fig. 4 shows a comparison of the cytotoxic effects of KP 1019, indazole and of
mixtures
of KP 1339 and indazole in the molar ratios 1:1 respectively 1:5 (administered
as a
solution in a conventional cell culture medium MEM, supplemented with 10% of
foetal
bovine serum, without the addition of organic solvents or dissolving agents)
on the
human line of tumour cells CH1 (ovarian carcinoma) in the MTT assay with
continuous
96 hour exposure to the active substance.
CA 02436260 2003-07-22
14
General manufacturing instructions
The manufacture of the compounds of the general formula (I) can take place
according
to the instructions described in WO 97/36595. Furthermore, the manufacture of
the
compounds of the general formula (III) can take place as shown in J. Cancer
Res. Clin.
Oncol. 1992, 118(3), pp. 195-200. The manufacture of the compounds of the
formulae
(II) and (IV) takes place according to known methods.
In the foilowing the invention is explained based on some examples.
Example 1
The compound sodium trans-[RuCI4(ind)2], KP1339, which is easily water-soluble
and
lyophilisable was reacted with indazolium hydrochloride to form a composition
(A)
according to the invention, containing indazolium trans-[tetrachlorobis(1 H-
indazole)-
ruthenate(III)] (KP 1019) and sodium chloride (see Fig. 1).
= / = /
HN% HN
N 600% N x HC/ -~- (` ~ NH+ CI~ ,,~CI
Na+ C~ RI u,CI + ~ Ru + ~1aCl
cl I CI H H C(~ CI
N~
~ NH NH
/ = / =
Figure 1: Formation of a composition (A) according to the invention,
containing
indazolium trans-[tetrachlorobis(1 H-indazole)-ruthenate(III)] (KP 1019) and
sodium
chloride, by the reaction of KP 1339 and indazolium hydrochloride.
CA 02436260 2003-07-22
Example 2
Cytotoxicity investigations were carried out on the composition obtained
according to
Example 1. The composition was obtained by reacting the sodium salt KP1339,
which
exhibits a water-solubility of more than thirty times higher than KP 1019,
with indazolium
hydrochloride in the infusion solution immediately before administration.
Since experiments on the stem cells of human solid tumours which were bred on
as
nude mice xenografts, and on continuous human tumour cell lines corresponded
in
showing that KP 1339 in vitro exhibits clearly weaker antiproliferative
effectiveness than
KP 1019, clarification was obtained in further experiments of how far the
stronger
activity of KP 1019 can be restored by the addition of indazole to solutions
of KP 1339.
The tumour inhibiting activity of the equimolar mixture of KP 1339 and
indazole proved
to be identical to that of the original KP 1019 (see Figures 1 and 2), whereas
pure KP
1339 was three to four times less effective than KP 1019. This has been
confirmed on
two tumour cell lines (SW480, CH1) and reproduced four times. In these
experiments
the lower effectiveness of KP 1339 in comparison to KP 1019 was confirmed.
Example 3
In the first experiments with compositions which had been obtained by reacting
KP 1339
with indazolium hydrochloride in the molar ratio of 1:1, it could be shown as
a result that
the cytotoxic activity of the original KP 1019 was attained. Further
experiments gave
insight into the manner in which an excess of indazole affected the
cytotoxicity.
The cytotoxic effects of KP 1019 and combinations of KP 1339 and indazole in
different
molar ratios (administered as solution in the conventional cell culture medium
MEM,
supplemented with 10% foetal bovine serum, without the addition of organic
solvents or
dissolving agents) have been comparatively investigated on the human line of
tumour
cells SW480 (colon carcinoma) and CH1 (ovarian carcinoma) in the MTT assay
under
the application of a continuous 96 hour exposure to the active substance.
CA 02436260 2003-07-22
16
It has been surprisingly shown that the tumour inhibiting activity can be
further
increased by the addition of an excess of indazole. A mixture of KP 1339 and
indazole
in the molar ratio of 1:5 gave a two to five times increase in the
cytotoxicity compared to
KP 1019 (see Figures 3 and 4). A molar ratio of 1:2 is already sufficient to
exceed the
effectiveness of the original KP 1019. Indazole itself only exhibits a
cytotoxic effect in
higher concentrations (> 1mM). The increase in the tumour inhibiting activity
of the
solutions which contain an excess of indazole cannot therefore be explained by
a purely
additive effect of the components, but is rather attributable either to a
synergistic effect,
a positive effect of the free indazole on the stability of the complex or on
an unknown
mechanism. The discontinuous trace of the dosage/effect curve on the cell line
SW480
which proved to be strictly reproducible in five independent experimental runs
indicates
a complex interaction between KP 1339 and indazole.
